Breaking News:

Article ID: 702339

Texas Biomed researchers – in collaboration with the University of Iowa – are trying to find out how malarial infections impact people exposed to Ebola virus. Both diseases are endemic in that region.

Article ID: 702257

Article ID: 701959

A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.

Article ID: 701256

A new study from the NYU College of Global Public Health and NYU Tandon School of Engineering, published in Nature Digital Medicine, used text message surveys to determine in real time how people used maternal health services during a recent Ebola outbreak and measured a drop in hospital-based births during the outbreak.

Article ID: 700447

Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.

Article ID: 699544

Geneticist Jason Ladner talks about the study, which underscores the need for focused prevention efforts among survivors and better capacity to detect new cases of the deadly virus.

Article ID: 698671

A new study at Texas Biomedical Research Institute is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication.

Article ID: 698593

A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.

Article ID: 698417

WASHINGTON — Georgetown University professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include infectious disease control and treatment, vaccine development, clinical trials, global health security, and international health regulations. To schedule an interview, please contact Karen Teber at km463@georgetown.

Article ID: 698263

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.